Can mouse models of cancer reliably improve clinical trial outcome

摘要: One of the major threats humankind faces today is cancer. Incidences neoplasia worldwide are estimated to translate 13 million cancer deaths by 2030. Despite promising response rates through treatment modalities such as surgical resection well chemo- and radiation therapy in a few entities, we still lack sufficient therapeutics that provide long-term survival patients, especially patients with advanced disease. Hence, accelerated translation highly encouraging vitro vivo preclinical therapeutic findings urgently needed meet demand for novel drugs combat mortality successfully. Genetically engineered mouse models recapitulating characteristics human disease have become an indispensable tool research predict clinical outcome. This commentary highlights current benefits limitations developing subsequently improve trial outcome humans.